loading
Precedente Chiudi:
$501.15
Aprire:
$501.45
Volume 24 ore:
336.77K
Relative Volume:
0.23
Capitalizzazione di mercato:
$127.64B
Reddito:
$11.02B
Utile/perdita netta:
$-535.60M
Rapporto P/E:
-229.01
EPS:
-2.2
Flusso di cassa netto:
$-978.00M
1 W Prestazione:
+1.56%
1M Prestazione:
+6.24%
6M Prestazione:
+0.87%
1 anno Prestazione:
+25.72%
Intervallo 1D:
Value
$498.02
$505.61
Intervallo di 1 settimana:
Value
$490.85
$510.77
Portata 52W:
Value
$377.85
$519.88

Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile

Name
Nome
Vertex Pharmaceuticals Inc
Name
Telefono
(617) 341-6393
Name
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Name
Dipendente
6,100
Name
Cinguettio
@VertexPharma
Name
Prossima data di guadagno
2025-02-10
Name
Ultimi documenti SEC
Name
VRTX's Discussions on Twitter

Confronta VRTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
504.19 127.64B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
606.69 65.95B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
655.87 37.92B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.03 32.98B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.16 26.89B 3.81B -644.79M -669.77M -6.24

Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-02-12 Aggiornamento Canaccord Genuity Sell → Hold
2025-02-11 Aggiornamento Canaccord Genuity Sell → Hold
2025-01-30 Downgrade Wells Fargo Overweight → Equal Weight
2024-12-20 Reiterato H.C. Wainwright Buy
2024-12-19 Downgrade Oppenheimer Outperform → Perform
2024-12-09 Aggiornamento Jefferies Hold → Buy
2024-11-14 Iniziato Citigroup Buy
2024-10-16 Iniziato Scotiabank Sector Perform
2024-10-10 Ripresa Raymond James Mkt Perform
2024-08-05 Downgrade Barclays Overweight → Equal Weight
2024-06-27 Iniziato Redburn Atlantic Buy
2024-04-11 Aggiornamento Evercore ISI In-line → Outperform
2024-02-15 Iniziato Wolfe Research Outperform
2024-02-06 Downgrade Evercore ISI Outperform → In-line
2024-02-02 Downgrade Bernstein Outperform → Mkt Perform
2024-01-31 Downgrade Maxim Group Buy → Hold
2024-01-31 Downgrade Robert W. Baird Neutral → Underperform
2024-01-24 Downgrade Canaccord Genuity Hold → Sell
2023-12-14 Reiterato RBC Capital Mkts Sector Perform
2023-05-30 Iniziato William Blair Outperform
2023-05-04 Ripresa Piper Sandler Overweight
2023-03-21 Iniziato Bernstein Outperform
2023-01-18 Iniziato Canaccord Genuity Hold
2023-01-17 Aggiornamento SVB Leerink Mkt Perform → Outperform
2022-12-19 Downgrade Jefferies Buy → Hold
2022-07-13 Iniziato Cantor Fitzgerald Overweight
2022-06-01 Aggiornamento Maxim Group Hold → Buy
2022-05-23 Iniziato SVB Leerink Mkt Perform
2022-05-06 Downgrade Robert W. Baird Outperform → Neutral
2022-05-03 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2022-02-03 Downgrade RBC Capital Mkts Outperform → Sector Perform
2022-01-27 Reiterato JP Morgan Overweight
2022-01-27 Reiterato Morgan Stanley Underweight
2022-01-27 Reiterato RBC Capital Mkts Outperform
2022-01-27 Reiterato Stifel Hold
2022-01-27 Reiterato Wolfe Research Outperform
2022-01-20 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-12-09 Iniziato Wells Fargo Overweight
2021-11-19 Iniziato BMO Capital Markets Market Perform
2021-11-19 Downgrade Piper Sandler Overweight → Neutral
2021-09-09 Downgrade Stifel Buy → Hold
2021-09-07 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-07-20 Downgrade SVB Leerink Mkt Perform → Underperform
2021-07-19 Ripresa Wolfe Research Outperform
2021-07-01 Iniziato Raymond James Mkt Perform
2021-06-11 Downgrade Daiwa Securities Outperform → Neutral
2021-02-23 Aggiornamento Robert W. Baird Neutral → Outperform
2021-02-02 Reiterato H.C. Wainwright Buy
2020-12-30 Iniziato Daiwa Securities Outperform
2020-11-30 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2020-11-20 Iniziato Bernstein Outperform
2020-10-28 Iniziato UBS Buy
2020-07-31 Reiterato H.C. Wainwright Buy
2020-07-08 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-04-30 Reiterato H.C. Wainwright Buy
2020-04-28 Downgrade RBC Capital Mkts Outperform → Sector Perform
2020-03-04 Iniziato Barclays Overweight
2020-01-31 Downgrade Robert W. Baird Outperform → Neutral
2019-11-19 Aggiornamento Guggenheim Neutral → Buy
2019-11-12 Iniziato SunTrust Buy
2019-10-17 Ripresa BofA/Merrill Buy
2019-09-03 Aggiornamento Goldman Neutral → Buy
2019-08-01 Downgrade Needham Buy → Hold
2019-05-23 Ripresa Citigroup Buy
2019-05-21 Iniziato Credit Suisse Outperform
2019-04-12 Iniziato Evercore ISI In-line
2019-03-26 Aggiornamento William Blair Mkt Perform → Outperform
2019-03-19 Downgrade SVB Leerink Outperform → Mkt Perform
2019-02-06 Downgrade Maxim Group Buy → Hold
Mostra tutto

Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie

pulisher
08:48 AM

Vertex Abandons AAV as Gene Therapy Space Weathers Difficulties - BioSpace

08:48 AM
pulisher
06:45 AM

3 No-Brainer Stocks to Buy in May - The Motley Fool

06:45 AM
pulisher
04:03 AM

Gilead and Vertex Pharma named among biotech’s tariff safe havens - MSN

04:03 AM
pulisher
May 04, 2025

How Will Vertex Pharmaceuticals Stock React To Its Upcoming Earnings? - Nasdaq

May 04, 2025
pulisher
May 04, 2025

Vertex Pharmaceuticals (VRTX) Earnings Preview: What to Expect - GuruFocus

May 04, 2025
pulisher
May 02, 2025

Vertex discontinues AAV research for gene therapies - Fierce Biotech

May 02, 2025
pulisher
May 01, 2025

As Journavx rollout begins, Vertex kicks off unbranded pain campaign with NFL alum Alex Smith - Fierce Pharma

May 01, 2025
pulisher
Apr 30, 2025

Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know - Yahoo Finance

Apr 30, 2025
pulisher
Apr 30, 2025

Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group - MSN

Apr 30, 2025
pulisher
Apr 30, 2025

What Analyst Projections for Key Metrics Reveal About Vertex (VRTX) Q1 Earnings - Nasdaq

Apr 30, 2025
pulisher
Apr 29, 2025

Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards? - Yahoo Finance

Apr 29, 2025
pulisher
Apr 28, 2025

Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance

Apr 28, 2025
pulisher
Apr 28, 2025

European regulators recommend new drugs from Vertex, Amgen and Jazz - Endpoints News

Apr 28, 2025
pulisher
Apr 28, 2025

, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire

Apr 28, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 25, 2025

US Health Secretary Reportedly Says 35 States to Join Pilot Program for Sickle Cell Disease Gene Therapies - marketscreener.com

Apr 25, 2025
pulisher
Apr 25, 2025

EMA Backs Vertex Pharmaceuticals' (VRTX) Alyftrek for Cystic Fib - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Vertex’s Alyftrek For CF Among Six Orphans On Track For Pan-EU Approval - insights.citeline.com

Apr 25, 2025
pulisher
Apr 24, 2025

Vertex Pharmaceuticals Stock (VRTX) Trending as Q1 Earnings Approach - TipRanks

Apr 24, 2025
pulisher
Apr 24, 2025

Vertex Pharmaceuticals (VRTX) Advances But Underperforms Market: Key Facts - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday - MSN

Apr 24, 2025
pulisher
Apr 23, 2025

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - MSN

Apr 23, 2025
pulisher
Apr 23, 2025

Vertex Pharmaceuticals’ Q1 2025 Earnings: What to Expect - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Vertex Pharmaceuticals’ Q1 2025 Earnings: What To Expect - Barchart.com

Apr 23, 2025
pulisher
Apr 22, 2025

Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom - MSN

Apr 22, 2025
pulisher
Apr 22, 2025

Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom - Barron's

Apr 22, 2025
pulisher
Apr 22, 2025

Vertex Pharmaceuticals (VRTX) Gains Favor with Increased Price T - GuruFocus

Apr 22, 2025
pulisher
Apr 22, 2025

Expert Outlook: Vertex Pharmaceuticals Through The Eyes Of 18 Analysts - Benzinga

Apr 22, 2025
pulisher
Apr 22, 2025

Vertex Pharmaceuticals (VRTX) Gains Favor with Increased Price Target | VRTX Stock News - GuruFocus

Apr 22, 2025
pulisher
Apr 22, 2025

ToolGen sues Vertex over alleged unlicensed use of CRISPR tech in gene therapy - koreabiomed.com

Apr 22, 2025
pulisher
Apr 21, 2025

Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely - Benzinga

Apr 21, 2025
pulisher
Apr 21, 2025

Vertex Pharmaceuticals (NasdaqGS:VRTX) Faces UK Patent Lawsuit Over Groundbreaking CASGEVY Therapy - simplywall.st

Apr 21, 2025
pulisher
Apr 21, 2025

ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom - Longview News-Journal

Apr 21, 2025
pulisher
Apr 19, 2025

Lobbying Update: $1,600,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq

Apr 19, 2025
pulisher
Apr 17, 2025

Reshma Kewalramani Among TIME’s 100 Most Influential People Of 2025 - IndiaWest

Apr 17, 2025
pulisher
Apr 17, 2025

Reshma Kewalramani among 2025 Time 100 most influential people - The American Bazaar

Apr 17, 2025
pulisher
Apr 17, 2025

Peering Into Vertex Pharmaceuticals's Recent Short Interest - Benzinga

Apr 17, 2025
pulisher
Apr 16, 2025

Reshma Kewalramani named among Time magazine's 100 most influential people - Firstpost

Apr 16, 2025
pulisher
Apr 15, 2025

Vertex’s Attempt to Redefine AKS Falls Short: Key Insights for Pharma Manufacturers - ArentFox Schiff

Apr 15, 2025
pulisher
Apr 15, 2025

Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $617 From $615, Maintains Buy Rating - marketscreener.com

Apr 15, 2025
pulisher
Apr 14, 2025

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis - BioSpace

Apr 14, 2025
pulisher
Apr 13, 2025

Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF R - GuruFocus

Apr 13, 2025
pulisher
Apr 12, 2025

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? - AOL.com

Apr 12, 2025
pulisher
Apr 12, 2025

Lobbying Update: $20,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq

Apr 12, 2025

Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$606.19
price up icon 0.02%
$655.79
price up icon 0.99%
$268.44
price up icon 3.75%
biotechnology ONC
$251.86
price down icon 1.02%
$101.25
price down icon 3.64%
Capitalizzazione:     |  Volume (24 ore):